Drugs / Ningmitai
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06159114 | Dec 2023 → Jan 2025 | chronic prostatitis | Xintian Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT05551221 | Jul 2022 → Dec 2023 overdue | benign prostatic hyperplasia | Xintian Pharmaceutical | Recruiting | No outcome recorded |
| Phase 4 | NCT06105827 | Oct 2016 → Apr 2019 | ureterolithiasis | Xintian Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ningmitai | “Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years.” NCT06159114 ↗ |
| Known as | Ningmitai Capsule | “Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years.” NCT06159114 ↗1“Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.” NCT06105827 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years.” NCT05551221 ↗ |
| Route | Oral | “Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.” NCT05551221 ↗ |